These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1531715)

  • 1. Mechanism of rejection of MHC class II-disparate murine skin grafts. I. Immunohistochemical analysis of T-cell subsets infiltrating the site of the graft.
    Kobayashi E; Fujiwara M
    Transplant Proc; 1992 Feb; 24(1):419-22. PubMed ID: 1531715
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of rejection of MHC class I-disparate murine skin grafts--histological and immunohistochemical studies of the rejection phenomenon.
    Kobayashi E; Kawai K; Ito M; Matsumoto Y; Fujiwara M
    Transplant Proc; 1990 Oct; 22(5):2352-7. PubMed ID: 2219400
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of rejection of MHC class I-disparate murine skin grafts. III. Are L3T4+ T cells involved in the rejection?
    Kobayashi E; Kawai K; Ikarashi Y; Watanabe H; Ito M; Fujiwara M
    Transplant Proc; 1991 Jun; 23(3):2008-11. PubMed ID: 1676551
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism of rejection of MHC class I-disparate murine skin grafts. II. Adoptive cell transfer experiments and immunohistochemical studies.
    Kobayashi E; Kawai K; Ikarashi Y; Watanabe H; Ito M; Fujiwara M
    Transplant Proc; 1991 Jun; 23(3):2005-7. PubMed ID: 2063472
    [No Abstract]   [Full Text] [Related]  

  • 5. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice.
    Benichou G; Valujskikh A; Heeger PS
    J Immunol; 1999 Jan; 162(1):352-8. PubMed ID: 9886406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice.
    Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D
    J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
    Koch U; Choksi S; Marcucci L; Korngold R
    J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The T cell populations mediating rejection of MHC class I disparate skin grafts in mice.
    Rosenberg AS
    Transpl Immunol; 1993; 1(2):93-9. PubMed ID: 7915953
    [No Abstract]   [Full Text] [Related]  

  • 9. Involvement of Th2-like T cells in regulating allograft reactivity against MHC class II-disparate antigen.
    Maeda H; Ogoshi S; Fujimoto S
    Transplant Proc; 1994 Apr; 26(2):847-8. PubMed ID: 8171685
    [No Abstract]   [Full Text] [Related]  

  • 10. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
    Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
    J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector cells must recognize antigens expressed in the graft to cause efficient skin graft rejection in SCID mice.
    Wecker H; Grusby MJ; Auchincloss H
    Transplantation; 1995 Apr; 59(8):1223-7. PubMed ID: 7732570
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
    Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
    J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody.
    Rosenberg AS; Finbloom DS; Maniero TG; Van der Meide PH; Singer A
    J Immunol; 1990 Jun; 144(12):4648-50. PubMed ID: 2112572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo.
    Fukuzawa M; Okada A; Shearer GM
    Transplant Proc; 1991 Dec; 23(6):2945-7. PubMed ID: 1721321
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence that a "four-cell cluster" may prime cytotoxic T-cells during graft rejection.
    Lee R; Glimcher LH; Auchincloss H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):847-9. PubMed ID: 8442245
    [No Abstract]   [Full Text] [Related]  

  • 16. Carcinogen-treated skin allografts rejected by T lymphocytes specific for class I but not class II MHC antigens.
    Halliday GM; Odling KA; Muller HK
    Cell Immunol; 1993 Oct; 151(2):291-9. PubMed ID: 8402936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of allorecognition and skin graft rejection in CD28 and CD40 ligand double-deficient mice.
    Habiro K; Kotani M; Omoto K; Kobayashi S; Tanabe K; Shimmura H; Suzuki K; Hayashi T; Toma H; Abe R
    Transplantation; 2003 Sep; 76(5):854-8. PubMed ID: 14501867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells.
    Rosenberg AS; Katz SI; Singer A
    J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance induction to murine class II MHC molecules by anti-CD4 antibody.
    Wheelahan J; McKenzie IF
    Transplant Proc; 1989 Feb; 21(1 Pt 1):246-7. PubMed ID: 2650112
    [No Abstract]   [Full Text] [Related]  

  • 20. Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection.
    Campos HH; Bach JF; Chatenoud L
    Transplant Proc; 1993 Feb; 25(1 Pt 1):798-9. PubMed ID: 8438486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.